Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells

Journal of Clinical Biochemistry and Nutrition

Volumn 51, Issue 2, 2012, Pages 122-127

  Teraoka, Mari ^a   Nakaso, Kazuhiro ^a   Kusumoto, Chiaki ^a   Katano, Satoshi ^a   Tajima, Naoko ^a   Yamashita, Atsushi ^a   Zushi, Teppei ^a   Ito, Satoru ^a   Matsura, Tatsuya ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

synuclein; Chlorogenic acid; Dopamine; Parkinson's disease; Polyphenol

Indexed keywords

ALPHA SYNUCLEIN; CHLOROGENIC ACID; DOPAMINE; POLYPHENOL;

ARTICLE; CATECHOLAMINE NERVE CELL; CELL STRAIN; CELL VIABILITY; CHEMICAL INTERACTION; COFFEE; CONTROLLED STUDY; CRYOPROTECTION; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; OLIGOMERIZATION; OXIDATION; PARKINSON DISEASE; STATISTICAL SIGNIFICANCE;

EID: 84865968044     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.D-11-00030     Document Type: Article

References (43)

1. Spillantini MG, Crowther RA, Jakes R, Masegawa M, Goedert M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-6473.
2. Mizuno Y, Hattori N, Kubo S, et al. Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 2008; 363: 2215-2227. (Pubitemid 351693531)
3. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
4. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011; 26: 1049-1055.
5. Singleton AB, Farrer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
6. Chatier-Harlin MC, Kachergus J, Roumier C, et al. α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-1169.
7. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169-1171. (Pubitemid 39296605)
8. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease. Nat Med 2002; 8: 600-606. (Pubitemid 34633438)
9. Ito S, Nakaso K, Imamura K, Takeshima T, Nakashima K. Endogenous catecholamine enhances the dysfunction of unfolded protein response and α-synuclein oligomerization in PC12 cells overexpressing human α-synuclein. Neurosci Res 2010; 66: 124-130.
10. Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 11282-11286.
11. Iwai A, Yoshimoto M, Masliah E, Saitoh T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995; 34: 10139-10145.
12. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neuosci 1988; 8: 2804-2815.
13. Fujiwara H, Hasegawa M, Dohmae N, et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-164.
14. Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009; 119: 3257-3265.
15. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-989.
16. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implication for Parkinson's disease. Science 2001; 293: 263-269. (Pubitemid 32694735)
17. De Franceschi G, Frare E, Pivato M, et al. Structural and morphological characterization of aggregated species of α-synuclein induced by docosahexaenoic acid. J Biol Chem 2011; 286: 22262-22274.
18. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003; 5: 165-176.
19. Miyazaki I, Asanuma M. Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem Res 2009; 34: 698-706.
20. Mazzulli JR, Armakola M, Dumoulin M, et al. Cellular oligomerization of α-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem 2007; 282: 31621-31630. (Pubitemid 350044848)
21. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's disease. J Nutr Biochem 2004; 15: 506-516. (Pubitemid 39209392)
22. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 2008; 33: 2416-2426.
23. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA 2000; 283: 2674-2679. (Pubitemid 30337329)
24. Nakaso K, Ito S, Nakashima K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci Lett 2008; 432: 146-150.
25. Masuda M, Suzuki N, Taniguchi S, et al. Small molecule inhibitors of α-synuclein filament assembly. Biochemistry 2006; 45: 6085-6094. (Pubitemid 43727101)
26. Masuda M, Hasegawa M, Nonaka T, et al. Inhibition of α-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett 2009; 583: 787-791.
27. Ikeda H, Kimura Y, Masaki M, Iwahashi H. Caffeic acid inhibits the formation of 1-hydroxyethyl radical in the reaction mixture of rat liver microsomes with ethanol partly through its metal chelating activity. J Clin Biochem Nutr 2011; 48: 187-193.
28. 3+ and NADPH. J Clin Biochem Nutr 2011; 49: 207-215.
29. Yoshimoto Y, Nakaso K, Nakashima K. L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett 2005; 579: 1197-1202. (Pubitemid 40248687)
30. Bisaglia M, Tosatto L, Munari F, et al. Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochem Biophys Res Commun 2010; 394: 424-428.
31. Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L. α-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 2010; 11: 41.
32. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the α-synuclein protofibril by dopamine-α-synuclein adduct. Science 2001; 294: 1346-1349. (Pubitemid 33063102)
33. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11: 1214-1221. (Pubitemid 43093669)
34. Xu Y, Stokes AH, Roskoski R Jr., Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 1998; 54: 691-697. (Pubitemid 28546072)
35. Whitehead RE, Ferrer JV, Javitch JA, Justice JB. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 2001; 76: 1242-1251. (Pubitemid 32167397)
36. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 2010; 33: 559-568.
37. Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with α-synuclein. J Biol Chem 2007; 282: 15597-15605. (Pubitemid 47093273)
38. Vinson JA. Flavonoids in foods as in vitro and in vivo antioxidants. Adv Exp Med Biol 1998; 439: 151-164. (Pubitemid 28429014)
39. Readerstorff D. Antioxidant activity of olive polyphenols in humans: a review. Int J Vitam Nutr Res 2009; 79: 152-165.
40. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res 2008; 33: 2416-2426.
41. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson's diseases. CNS Neurosci Ther 2008; 14: 352-365.
42. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010; 78: 466-477.
43. Mythri RB, Harish G, Dubey SK, Misra K, Bharath MM. Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease. Mol Cell Biochem 2011; 347: 135-143.